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Myasthenia gravis (MG) is characterized by reduced muscle endurance and is often accompanied by respiratory complications.
Improvement of respiratory function is therefore an important objective in MG therapy. A previous study demonstrated that
respiratory muscle endurance training (RMET) over four weeks increased respiratory muscle endurance of MG patients to about
200% of baseline. The purpose of the present study was to establish an appropriate maintenance training and to test its eﬀects
over four months. Ten patients with mild to moderate MG participated in this study. During the ﬁrst month, they performed ﬁve
training sessions per week. For the following 3 months, training frequency was reduced to ﬁve sessions per two weeks. Myasthenia
score, lung function, and respiratory endurance were determined prior to training, after the ﬁrst month, and after 4 months.
Myasthenia score improved from 0.71 ± 0.1t o0 .56 ± 0.1( P = 0.007). Respiratory endurance time increased from 6.1 ± 0.8t o
20.3 ± 3.0 min (P<0.001). In conclusion, this RMET maintenance program is feasible and is signiﬁcantly beneﬁcial for MG
patients.
1.Introduction
Myasthenia gravis (MG) is an autoimmune disease charac-
terized by blockade of the neuromuscular synapse. Hence,
muscle strength and, particularly, endurance are reduced,
ensuing in increased muscular fatigue [1, 2]. In most MG
patients, the entire muscular system is concerned, and
this may also involve respiratory muscles. Despite normal
spirometric values, patients with generalized MG often
presentacharacteristic“myasthenicpattern”withdecreasing
respiratory volumes during MVV [3] and reduced respira-
tory muscle endurance [2]. Respiratory muscle dysfunction
can further deteriorate patients’ physical ﬁtness and evoke
upper airway obstruction [4], sleep apnea [5, 6], or even
respiratory failure as the characteristic feature of myasthenic
crisis [7, 8]. Improvement of respiratory muscle function is
therefore an important objective in MG therapy.
In addition to pharmacological or operative treatment,
exercise therapy can be used as an adjuvant method in
therapy of MG [9, 10]. Besides general exercise programs,
speciﬁc respiratory muscle training could be beneﬁcial espe-
cially for patients with compromised respiratory function.
Positive eﬀects of respiratory muscle training on respiratory
muscle strength and endurance in patients with pulmonary
disorders were demonstrated for the ﬁrst time by Keens
et al. [11]. Likewise, in patients with neuromuscular diseases
respiratory dysfunction due to inadequate function of res-
piratory muscles is a strong rationale for a speciﬁc training
of respiratory muscles. Numerous studies on respiratory
muscle training have been performed in patients with
spinal cord injury [12, 13], postpolio syndrome [14], or
with neuromuscular disorders such as Duchenne’s muscular
dystrophyorspinalmuscularatrophy[15,16]demonstrating2 Autoimmune Diseases
improvement of lung function and of respiratory muscle
strength and/or endurance.
In contrast, there is only little experience with speciﬁc
respiratory training in MG patients [18–20]. These studies
reported beneﬁcial eﬀects of respiratory training on respi-
ratory muscle strength and/or lung function. None of these
studies applied sustained hyperpnea for training. However,
maintenance of an elevated level of ventilation over a longer
period of time such as in situations of increased physical
activity would be an appropriate training for patients with
increased respiratory muscle fatigue.
Several years ago, we used a normocapnic hyperp-
nea training that had been previously applied in healthy
untrained and trained subjects [21–23]a sw e l la si np a t i e n t s
with chronic obstructive pulmonary disease (COPD) [24,
25]. This type of respiratory muscle endurance training
(RMET) has also been applied in MG patients in a previous
study [26]. Four weeks of this normocapnic hyperpnea
training in MG patients resulted in a more than twofold
enhancementofrespiratorymuscleenduranceasreﬂectedby
time to exhaustion (TLim) and total ventilated volume (VLim)
in a respiratory endurance (RE) test. However, this gain
in respiratory muscle endurance reduced after termination
of the training period. Maintaining improved respiratory
muscle endurance requires to regularly continue RMET. This
might be hampered by strenuousness and expenditure of
time associated with the training. Therefore, the aim of
the present study was to establish a maintenance training
program and to test it for feasibility and beneﬁt with respect
to respiratory muscle endurance, MG symptoms, and lung
function.
2. Methods
2.1. Subjects. The patients involved in this study were
regularly consulting two neurologists specialized in MG
who were involved in this study (IB, PK). We chose 27
patients with mild to moderate generalized MG (degree II
according to MGFA classiﬁcation [17], degree 1–3 according
to Oosterhuis classiﬁcation [1]) as possible participants.
They have been suﬀering from MG for 1–39 years. Patients
with ocular symptoms only and hospitalized patients were
excluded. Eleven of the preselected patients resigned from
participation in the training study due to problems with
transportation or with their time schedule (5 patients), or
because they felt no need of respiratory training (6 patients).
Six patients tried the use of the training device but did not
manage the rebreathing technique, the use of the training
device, and the training frequency. In the end, 10 patients
(5 male, 5 female, average age 60 ± 4.2y) participated
in the study. Characteristics of these patients are given in
Table 1. Five of them had already participated in our ﬁrst
RMET study several years ago [26]. All participants had
experienced respiratory symptoms or problems in the past
due to their myasthenia and, for this reason, were moti-
vated to perform the respiratory endurance training. Seven
patients had additional chronic diseases; ﬁve suﬀered from
arterialhypertension,twoofthemadditionallyfromdiabetes
mellitus. One patient had a coronary heart disease, and one
other patient had a Lupus erythematodes. All patients were
free from chronic respiratory diseases. None of the patients
smoked at present. Two patients were ex-smokers but had
ceased smoking at least ﬁfteen years before. All participating
patients gave their written informed consent. The study was
approved by the local ethics committee.
2.2. Study Protocol. The study consisted of two phases.
Phase 1 included a four-week training period; during phase
2, the training was continued for another three months.
The protocol of phase 1 was the same as applied in the
ﬁrst study [26] but without a detraining period. In brief,
all patients including those who had already participated
in the previous study received a detailed explanation and
demonstration of all testing and training details and then
practiced the use of the training device at home for one
week 10min per day. The pretraining tests (baseline, B)
were performed 6–8 weeks later. They contained an MG
score (Besinger score [17, 27]), lung function testing, and
an RE test. For lung function tests including spirometry and
maximal voluntary ventilation (MVV) and for the RE test,
we used a metabolic cart (MetaMax 3B, Cortex Biophysik
GmbH, Leipzig, Germany). Additionally, respiratory muscle
strength (maximum inspiratory pressure, PImax)a tr e s i d u a l
volume (RV) was determined (resPImax,A n d o s ,H a m b u r g ,
Germany). For the RE test, patients connected their training
devicetothemetaboliccartandbreathedwithatidalvolume
(VT) ranging between 50 and 75% of VC at a rate of 25–40
breaths per minute at normocapnic conditions. This set-up
was intended to induce test termination after a maximum
of 10–12min. Criteria to terminate the test were patients’
perception of exhaustion or reduction in ventilation ( ˙ VE)
by more than 10% of the target for 1min. This test was
accomplished at least two times on separate days with the
best test being evaluated. We measured endurance time
(TLim: time until test termination) and endurance volume
(VLim: total volume breathed during the test, calculated as
TLim multiplied by ˙ VE).
The normocapnic hyperpnea training started after com-
pletion of the baseline tests. During phase 1, all patients
accomplished 20 training sessions in a period of 4–6 weeks
with about ﬁve training days and two resting days per
week. Each training session lasted 30min. Patients achieved
isocapnia by using a portable rebreathing device as described
in detail by Markov et al. [23], thus performing partial
rebreathing.Patientswerecarefullycoachedbeforehandtobe
attentivetosensationsofairhungerordizzinessassymptoms
of hypercapnia or hypocapnia. Additionally, we repeatedly
performed pCO2 measurements in the laboratory to assure
normocapnia. Target values of ˙ VE, VT, and breathing rate
(fR) were deﬁned in the same range as in the previous study
[26], that is, ˙ VE: 50–60% of individual MVV, VT: 50–60%
of VC, fR: 25–35min−1. Patients were instructed to perform
the training at home always at the same time of a day and at a
constant time interval after medication. After each training
session, they had to ﬁll in a short questionnaire regarding
changes in MG symptoms (see Appendix) and to assess
occurrence and degree of air hunger and respiratory eﬀort
using visual analogue scales. Moreover, after each trainingAutoimmune Diseases 3
Table 1: Characterization of patients participating in respiratory endurance training.
Patient Gender Age (y) BMI (kg/cm2)
MG degree
Diagn. (y)
Medication
MGFA OO ChEI (mg/d) IT (mg/d)
1 F 43 29.3 IIa 2 2 180
2 M 62 27.4 IIa 2 9 420 100
3 F 33 19.4 IIb 3 11 240
4 M 66 32.4 IIa 2 9 100
5 M 75 25.9 IIa 2 4 300
6 F 54 23.9 IIa 2 15 105
7 F 63 30.7 IIa 2 39 240
8 M 68 26.4 IIa 1 2 150
9 F 73 26.6 IIa 2 2 420
10 M 67 30.5 IIa 2 2 310
M: male; F: female; BMI: body mass index; MG degree: degree of myasthenia gravis according to classiﬁcations of MGFA (Myasthenia Gravis Foundation of
America [17]) and OO (Oosterhuis [1]); Diagn.: years since MG diagnosis; ChEI: cholinesterase inhibitors; IT: immunotherapy with azathioprine.
session they documented date, time of day, duration of
session, estimated breath volume, pacing frequency, and, if
necessary, problems or remarks.
During training phase 1, patients came at least two
times to the laboratory and performed a training session
with the device connected to the metabolic cart to assure
correct performance and normocapnia during training.
Additionally, we contacted all patients twice a week to ask
for problems with the training or with their MG symptoms.
At least 10 days after completion of the last training
session, a posttraining test series (P1) was carried out in the
same way as the baseline test series. All examinations were
performed at the same time of day as the pretraining tests.
For RE test, ˙ VE, VT,a n dfR were set to the same values as in
the baseline test.
Training phase 2 started after conclusion of all P1 tests.
In phase 2, training frequency was reduced to 5 training
sessions per two weeks. Training settings were the same as in
phase 1. One training session per month was performed in
the laboratory to check correctness of training performance.
Patients were phoned once per week to ask for possible
problems, for MG symptoms, and for their subjective
experience with training. At the end of phase 2, patients
performed another posttraining test series (P4) identical to
B and P1 tests. The patients were then asked to continue the
training, and all participants agreed.
2.3. Data Analysis. A l lv a l u e sa r eg i v e na sm e a nv a l u e s±
SEM. We evaluated Besinger score, vital capacity (VC),
forced expiratory volume in 1s (FEV1), peak expiratory
ﬂ o w( P E F ) ,M V V ,P I max, TLim,a n dVLim. Comparisons
between the three test periods (B, P1, P4) were performed
using a repeated measures analysis of variance with posthoc
multiple comparisons according to the Holm-Sidak method.
Additionally, when a signiﬁcant diﬀerence was detected,
a multiple linear regression was performed to describe
the relationship of this respective variable with time (days
since baseline tests) and with training (cumulated volume
breathed during training).
3. Results
3.1. Training Course. All patients completed at least 50
training sessions with 30min training time per session as
required. No complications were reported during the total
observation time. In 8 patients, MG was stable throughout
the time without change in medication or outpatient care
by their neurologist. One patient (no. 7) got a respiratory
infection at the beginning of phase 2 and received additional
cholinesterase inhibitors for 4 weeks. In one other patient
(no. 10) MG symptoms had slightly deteriorated 5 weeks
prior to the training period so that he transiently needed a
higher dose of cholinesterase inhibitors. During training, his
symptoms gradually improved, and his medication could be
adequately reduced.
3.2. Besinger Score of MG Symptoms. Besinger score ranges
from 0 to 3 with 0 meaning the best value, that is, no myas-
thenic symptoms, and 3 meaning most severe symptoms
[17, 27]. The participants of the study achieved a baseline
Besingerscoreof0.71 ±0.12.Trainingsigniﬁcantlyimproved
the score (P = 0.007). After phase 1 training period, the
improvementwasnotsigniﬁcant(0.63 ±0.11,P = 0.09),but
afterphase2,wefoundasigniﬁcantscorereductionto0.56 ±
0.10 (P = 0.002, Figure 1). A multiple linear regression
showed no signiﬁcant correlation with training (P = 0.09)
or with time (P = 0.19). No deterioration in myasthenia
symptoms related to respiratory training was reported in the
training questionnaire.
3.3.LungFunction. Baselinelungfunctionwasnormalforall
patients with VC being 95.5 ± 3.7%, FEV1 90.5 ± 3.6%, PEF
86.9 ± 4.5%, MVV 93.8 ± 6.6%, and maximal inspiratory
pressure (PImax) 75.1 ± 5.4% predicted. RMET induced mild
but not signiﬁcant increases in VC (P1: 95.9 ± 3.5%, P4:
99.2 ± 4.1%, P = 0.39), FEV1 (P1: 93.1 ± 2.7%, P4: 96.3 ±
3.8%, P = 0.28), PEF (P1: 90.0 ± 4.8%, P4: 95.7 ± 5.4%, P =
0.07), MVV (P1: 95.6 ± 6.0%, P4: 101.0 ± 6.5%, P = 0.24),
and PImax (P1: 79.2 ± 5.4%, P4: 78.0 ± 6.4%, P = 0.42).
Absolute values are given in Table 2.4 Autoimmune Diseases
Table 2: Lung function data.
Patient VC (L) FEV1 (L) PEF (L s−1)M V V ( L m i n −1)P I max (kPa)
B P1 P4 B P1 P4 B P1 P4 B P1 P4 B P1 P4
1 3.8 4.1 4.2 3.1 3.3 3.9 7.1 6.2 7.6 142 150 133 9.1 9.4 9.5
2 3.9 3.8 4.0 3.1 3.1 3.1 8.6 8.0 8.4 138 131 188 9.5 10.9 11.4
3 3.1 3.4 3.3 2.3 2.6 2.4 4.5 5.1 4.7 74 73 84 5.6 6.9 7.0
4 3.7 3.7 3.6 2.9 3.2 2.9 7.6 9.4 9.0 130 152 144 8.9 8.9 8.3
5 3.7 3.4 3.5 2.8 2.5 2.5 7.7 7.8 8.9 124 121 114 4.3 5.3 5.3
6 3.9 3.6 4.4 2.7 2.6 3.5 4.7 5.3 7.2 73 89 105 6.6 5.8 6.3
7 2.8 2.7 2.6 2.1 2.1 2.0 4.9 5.1 4.4 91 91 97 5.6 6.6 5.1
8 4.6 4.7 4.4 3.1 2.9 2.9 7.0 7.4 7.4 162 154 155 8.1 9.0 9.3
9 2.6 2.6 2.8 2.1 2.4 2.3 4.6 4.4 5.1 76 75 81 5.9 5.1 4.6
10 2.7 2.9 3.5 1.9 2.2 2.5 7.1 7.6 7.5 94 92 90 5.9 5.8 6.1
Mean 3.5 3.5 3.6 2.6 2.7 2.8 6.4 6.6 7.0 110 113 119 6.7 7.1 7.1
SEM 0.20 0.20 0.20 0.15 0.13 0.18 0.49 0.52 0.53 10.3 10.3 11.1 0.57 0.67 0.75
VC; vital capacity; FEV1; forced expiratory volume in 1s; PEF; peak expiratory ﬂow; MVV; maximal voluntary ventilation; PImax; maximal inspiratory
pressure. B; baseline values; P1; posttraining test after 4 weeks of training (phase 1); P4; posttraining test after 4 months of training (phase 2).
3.4. Respiratory Endurance Tests. In the baseline RE test,
patients achieved an average time to exhaustion (TLim)o f
6.1 ± 0.8min at an average ventilation of 58.9 ± 4.7Lmin−1
corresponding to 54.7 ± 2.5% MVV. The patients breathed
during TLim at o t a lv o l u m e( VLim)o f3 8 2± 78L. RMET
signiﬁcantly increased TLim and VLim (P<0.001). After four
weeks, TLim reached 15.1 ± 2.8min and VLim 995 ± 243L.
Prolonged training further increased TLim to 20.3 ± 3.0min
(Figure 2)a n dVLim to 1316 ± 275L (Figure 3). A multiple
linearregressionshowed signiﬁcantcorrelationwithtraining
and with time (P<0.001) for VLim. TLim was signiﬁcantly
correlated with training (P = 0.005) but not with time
(P = 0.10).
4. Discussion
In the present study, we established and evaluated a home-
based RMET program appropriate for long-term application
in patients with mild to moderate myasthenia gravis. A
tight control consisting of a careful training documen-
tation and self-reported questionnaires, frequent phone
calls, and regular laboratory tests ensured adequate training
performance. The results demonstrated that 30min nor-
mocapnic hyperpnea training 2-3 times per week over 3
months induced further improvement of respiratory muscle
endurance additionally to the gain achieved after a 4-week
intensive training period (phase 1).
The results of phase 1 conﬁrm our previous results
obtained with the same training program, that is, 30min
normocapnic hyperpnea training 5 times per week over 4
weeks [26].Mostoftheparticipantsofthepreviousstudyfelt
the number of training sessions per week being too high to
perform the RMET program regularly over a long time. The
reduced training frequency applied in phase 2 was acceptable
foralloftheparticipants;therefore,allagreedtocontinuethe
RE training for at least 3 further months.
We had expected the training program in phase 2 to
maintain respiratory endurance expressed by TLim and VLim
Besinger score
0
0.3
0.6
0.9
BP 1 P 4
∗
Figure 1: Besinger score of myasthenic symptoms before (B) and
after 4 weeks (P1) and 4 months (P4) of respiratory endurance
training. Data are presented as mean ± SEM; ∗signiﬁcant diﬀerence
versus B.
at the enhanced level achieved after phase 1 (about 250% of
baseline). However, even with the lower training frequency,
TLim and VLim further increased during the following 3
months to about 340% of baseline.
Moreover, myasthenia symptoms indicated by Besinger
scoreimprovedsigniﬁcantlycomparedtobaseline.Afterfour
weeks of training (phase 1), we only observed a tendency
to improvement, thus conﬁrming results of our previous
study [26]. During phase 2, enhancement of Besinger score
progressedandreachedsigniﬁcanceafter4monthsofRMET.
Correspondingly, patients reported subjective improvement
of their general state, reduced exhaustion in many activities
of daily life, and attenuation of myasthenia symptoms.
Recent reviews on exercise therapy, especially respiratory
muscle training, in neuromuscular disease demonstrated
limited positive eﬀects of training therapy on pulmonary
rehabilitation, exercise tolerance, and quality of life [28, 29].Autoimmune Diseases 5
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Figure 2: Respiratory endurance time (TLim (min)) before (B) and
after 4 weeks (P1) and 4 months (P4) of respiratory endurance
training. Data are presented as mean ± SEM; ∗signiﬁcant diﬀerence
versus B, ◦signiﬁcant diﬀerence between P1 and P4.
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Figure 3:Totalvolumeventilatedduringrespiratoryendurancetest
(VLim (L)) before (B) and after 4 weeks (P1) and 4 months (P4) of
respiratory endurance training. Data are presented as mean ± SEM;
∗signiﬁcant diﬀerence versus B.
RMET improved lung function (VC, FEV1,P E F ,M V V ,
PImax) of MG patients slightly but not signiﬁcantly. Lung
function parameters such as VC, FEV1,P E F ,a n dP I max are
based on short maneuvers requiring maximal eﬀort. These
abilities are usually not reduced in patients with mild to
moderate MG. All of our patients had normal lung function
atbaselinereﬂectingamoderatedegreeofrespiratorymuscle
weakness. A signiﬁcant reduction of total lung capacity and
hence, of VC can be expected when inspiratory muscle force
isreducedbyabout50%[30].Inhealthysubjects,respiratory
endurance training had no eﬀect on lung function [21, 22].
Training eﬀects also depend on duration and intensity of
training. This is expressed by signiﬁcant correlation of TLim
and VLim with cumulated volume breathed during total
training time. In MG patients, respiratory muscle training
at 6 days per week over 3 months signiﬁcantly improved
static lung volumes such as VC and FEV1[18]. Accordingly,
we observed further increase in these volumes during phase
2 of RMET in our patients. An 8-week inspiratory muscle
trainingperformedthreetimesperweekdidnotsigniﬁcantly
change FVC and FEV1 but signiﬁcantly improved MVV and
PImax [20].TheincreaseinMVVwas8%intheirstudywhich
was in a similar range as in our study.
The diﬀerent eﬀects of respiratory muscle training on
lung function might also be explained by the training
speciﬁcity of respiratory muscle training as already described
by Leith and Bradley [31] who showed that respiratory
strength training mainly improved maximal force. This is
reﬂected in the two studies mentioned above [18, 20].
Their training programs were predominantly directed on
respiratory muscle strength training, and both groups found
a signiﬁcant increase in PImax. On the contrary, respira-
tory endurance training predominantly improves endurance
whichmaybeaccompaniedbyamildpositiveeﬀectonforce.
Improved respiratory endurance is even more important
than improvement of lung function parameters in MG
patients. Weakness and fatigue of respiratory muscles is
responsible for dyspnea and reduced exercise tolerance and
thus, can compromise quality of life and increase the risk of
respiratory failure [32]. In healthy subjects, RMET reduced
respiratory muscle fatigue and increased cycling endurance
in those subjects who had presented more than 10% of
diaphragm or abdominal muscle fatigue in a pretraining
exhaustion test [33]. As increased muscular fatigue is a
characteristic feature of MG, a similar outcome had been
expected for MG patients and was reﬂected in enhanced TLim
and VLim. Moreover, all our patients perceived beneﬁt of
the training in terms of improved respiration and relief of
respiratory symptoms. None of them reported any adverse
eﬀects. This is reﬂected best in the fact that all participants
agreed to continue the training study.
Limitations of the Study. The main limitation of this study is
thelackofacontrolgroup.Thestudyprogramwasstrenuous
and, particularly in phase 1, time consuming. Even the
control program would have needed much time and eﬀort
as control patients also had to complete all laboratory tests.
Hence, those patients who had resigned from training also
refused to serve as controls. Participation in the RE training
study required high motivation. Six patients who were asked
for participation in this study refused as they did not see
a necessity to perform this training. On the other hand,
patients who had respiratory symptoms or had experienced
respiratory disturbances in their past were highly motivated
to perform the respiratory endurance training but were not
willingtoserveasnontrainingcontrols.Forthesereasons,no
control group could be formed.
Moreover, RMET cannot be applied to all MG patients.
Some patients may not cope with the technique, and patients
with severe MG are not able to perform this training at
suﬃcient intensity. For patients with mild to moderate
MG, this normocapnic hyperpnea training is appropriate if
patients are motivated to learn the technique and to subject
tothetimeneedandeﬀortofthetraining.Thesepatientscan
considerably improve their respiratory muscle endurance.6 Autoimmune Diseases
A long-term endurance training program is expected
to improve muscle endurance by inducing muscular hyper-
trophy. In the present study, we could not clarify whether
reduced perception of respiratory eﬀort rather than true
respiratory muscle hypertrophy caused the improvements
observed in the study. A recent reevaluation of 15 years of
RMET experience in healthy subjects revealed that enhanced
muscle endurance after RMET was unlikely due to reduced
adverse respiratory sensations [34]. However, this does not
preclude other factors such as improved neuromuscular
coordination that may contribute to the RMET eﬀect.
In conclusion, the study demonstrated that respiratory
endurance training can be performed safely in patients with
mild or moderate MG over several months. It indicates that
this training program could be appropriate for long-term,
ideally life-long, application resulting in improvement of
respiratory muscle endurance and myasthenia symptoms.
Appendix
Self-Reported TrainingQuestionnaire
Theoriginalquestionnaireaspresentedtothepatientswasin
German.
Training session no.: ... Date: ...
Have symptoms of your myasthenia changed after
this training?
Yes
No
If yes, which symptoms/functions have deteriorated?
  Ptosis
  Double vision
  Swallowing problems/dysphagia
  Chewing problems
  Pursing lips/whistling
  Neck strength (e.g., diﬃculties with holding
your head up?)
  Armstrength(e.g.,problemswithhair-drying?)
  Leg strength (e.g., diﬃculties with climbing a
staircase?)
How long did this deterioration continue? ...
Was additional medication (cholinesterase
inhibitors) necessary?
Yes
No
Did you have to interrupt or break oﬀ this training
due to deterioration of MG symptoms?
Yes
No
Further remarks concerning your current state: ...
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